Logo

Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

Share this

Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

Shots:

  • The approval was based on a P-I/II (ONO-4059-02) study evaluating the efficacy and safety of Velexbru (320/480mg, PO, qd) monothx. in 44 patients with recurrent or refractory PCNSL
  • The results showed ORR {52.9% (9/17)} as assessed by an IRC in patients who received 480mg of Velexbru in the fasting with an approved dosage, grade 3 - 4 adverse drug reactions were observed in 11.8% (2/17) patients
  • Velexbru is a highly selective, oral BTK inhibitor & has received manufacturing and marketing approval of Velexbru in Japan in March 2020 and launched in May 2020 for the treatment of r/r PCNSL. The therapy has received approval for the additional indication of WM and LPL

 Ref: Ono | Image: Ono USA

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions